{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:28:26Z","timestamp":1785583706478,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,5]]},"DOI":"10.7759\/cureus.83487","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T07:37:59Z","timestamp":1746430679000},"source":"Crossref","is-referenced-by-count":1,"title":["Rivaroxaban Treatment in Pediatric Patients With Hematologic Malignancies and Venous Thromboembolism: A Report of Four Cases"],"prefix":"10.7759","author":[{"given":"Ryohei","family":"Fukunaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Itabashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11122397","article-title":"State-of-art in the age determination of venous thromboembolism: a systematic review","volume":"11","author":"Di Fazio N","year":"2021","unstructured":"Di Fazio N, Delogu G, Ciallella C, Padovano M, Spadazzi F, Frati P, Fineschi V. State-of-art in the age determination of venous thromboembolism: a systematic review. Diagnostics (Basel). 2021, 11:2397. 10.3390\/diagnostics11122397","journal-title":"Diagnostics (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960240207","article-title":"Clinical characteristics of acute pulmonary thromboembolism in Japan: results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research","volume":"24","author":"Nakamura M","year":"2001","unstructured":"Nakamura M, Fujioka H, Yamada N, et al.. Clinical characteristics of acute pulmonary thromboembolism in Japan: results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol. 2001, 24:132-8. 10.1002\/clc.4960240207","journal-title":"Clin Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s003800200036","article-title":"Prognostic significance of early diagnosis in acute pulmonary thromboembolism with circulatory failure","volume":"17","author":"Ota M","year":"2002","unstructured":"Ota M, Nakamura M, Yamada N, et al.. Prognostic significance of early diagnosis in acute pulmonary thromboembolism with circulatory failure. Heart Vessels. 2002, 17:7-11. 10.1007\/s003800200036","journal-title":"Heart Vessels"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.25283","article-title":"Comparative effectiveness of anticoagulants in patients with cancer-associated thrombosis","volume":"6","author":"Riaz IB","year":"2023","unstructured":"Riaz IB, Fuentes H, Deng Y, et al.. Comparative effectiveness of anticoagulants in patients with cancer-associated thrombosis. JAMA Netw Open. 2023, 6:e2325283. 10.1001\/jamanetworkopen.2023.25283","journal-title":"JAMA Netw Open"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.06.002","article-title":"Venous thromboembolism incidence in hematologic malignancies","volume":"33","author":"Kekre N","year":"2019","unstructured":"Kekre N, Connors JM. Venous thromboembolism incidence in hematologic malignancies. Blood Rev. 2019, 33:24-32. 10.1016\/j.blre.2018.06.002","journal-title":"Blood Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18397","article-title":"A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: different practices of assessment and management","volume":"199","author":"Andersson NG","year":"2022","unstructured":"Andersson NG, Rathe M, M\u00f8lle I, et al.. A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: different practices of assessment and management. Br J Haematol. 2022, 199:117-21. 10.1111\/bjh.18397","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/children11091096","article-title":"Thrombotic complications in pediatric cancer","volume":"11","author":"Adramerina A","year":"2024","unstructured":"Adramerina A, Economou M. Thrombotic complications in pediatric cancer. Children (Basel). 2024, 11:1096. 10.3390\/children11091096","journal-title":"Children (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102541","article-title":"Proportion and risk factors for hospital-acquired venous thromboembolism in children: a systematic review and meta-analysis of data from 20 million individuals in 22 countries","volume":"8","author":"Zhou J","year":"2024","unstructured":"Zhou J, Zhu Y, Liu Y, Zhan H, Niu P, Chen H, Zhang J. Proportion and risk factors for hospital-acquired venous thromboembolism in children: a systematic review and meta-analysis of data from 20 million individuals in 22 countries. Res Pract Thromb Haemost. 2024, 8:102541. 10.1016\/j.rpth.2024.102541","journal-title":"Res Pract Thromb Haemost"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1448085","article-title":"Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review","volume":"59","author":"Sorigue M","year":"2018","unstructured":"Sorigue M, Orna E, Sancho JM. Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review. Leuk Lymphoma. 2018, 59:2602-11. 10.1080\/10428194.2018.1448085","journal-title":"Leuk Lymphoma"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1373635","article-title":"Efficacy and safety of direct oral anticoagulants for preventing venous thromboembolism in hospitalized cancer patients: a national multicenter retrospective cohort study","volume":"15","author":"Wu S","year":"2024","unstructured":"Wu S, Wang H, Li C, et al.. Efficacy and safety of direct oral anticoagulants for preventing venous thromboembolism in hospitalized cancer patients: a national multicenter retrospective cohort study. Front Pharmacol. 2024, 15:1373635. 10.3389\/fphar.2024.1373635","journal-title":"Front Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male C","year":"2020","unstructured":"Male C, Lensing AWA, Palumbo JS, et al.. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020, 7:18-27. 10.1016\/S2352-3026(19)30219-4","journal-title":"Lancet Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018966","article-title":"How I treat pediatric venous thromboembolism in the DOAC era","volume":"143","author":"Bhat RV","year":"2024","unstructured":"Bhat RV, Young G, Sharathkumar AA. How I treat pediatric venous thromboembolism in the DOAC era. Blood. 2024, 143:389-403. 10.1182\/blood.2022018966","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29888","article-title":"Rivaroxaban treatment among children with cancer-associated thromboembolism: real-world data","volume":"69","author":"Barg AA","year":"2022","unstructured":"Barg AA, Levy-Mendelovich S, Gilad O, et al.. Rivaroxaban treatment among children with cancer-associated thromboembolism: real-world data. Pediatr Blood Cancer. 2022, 69:e29888. 10.1002\/pbc.29888","journal-title":"Pediatr Blood Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00811","article-title":"JCCG ALL-B12: evaluation of intensified therapies with vincristine\/dexamethasone pulses and asparaginase and augmented high-dose methotrexate for pediatric B-ALL","volume":"43","author":"Kato M","year":"2025","unstructured":"Kato M, Okamoto Y, Imamura T, et al.. JCCG ALL-B12: evaluation of intensified therapies with vincristine\/dexamethasone pulses and asparaginase and augmented high-dose methotrexate for pediatric B-ALL. J Clin Oncol. 2025, 43:567-77. 10.1200\/JCO.24.00811","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0973","article-title":"The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95","volume":"105","author":"Woessmann W","year":"2005","unstructured":"Woessmann W, Seidemann K, Mann G, et al.. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005, 105:948-58. 10.1182\/blood-2004-03-0973","journal-title":"Blood"},{"key":"ref16","article-title":"The effect of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin\u2019s lymphoma (HL-14): protocol for a Phase II study","volume":"72","author":"Koga Y","year":"2018","unstructured":"Koga Y, Baba S, Fukano R, et al.. The effect of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin\u2019s lymphoma (HL-14): protocol for a Phase II study. Acta Med Okayama. 2018, 72:437-40.","journal-title":"Acta Med Okayama"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.39.1038","article-title":"Clinical features and predictors of in-hospital mortality in patients with acute and chronic pulmonary thromboembolism","volume":"39","author":"Kumasaka N","year":"2000","unstructured":"Kumasaka N, Sakuma M, Shirato K. Clinical features and predictors of in-hospital mortality in patients with acute and chronic pulmonary thromboembolism. Intern Med. 2000, 39:1038-43. 10.2169\/internalmedicine.39.1038","journal-title":"Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.855162","article-title":"Challenges in management of VTE in children with cancer: risk factors and treatment options","volume":"10","author":"Samji N","year":"2022","unstructured":"Samji N, Bhatt MD, Kulkarni K. Challenges in management of VTE in children with cancer: risk factors and treatment options. Front Pediatr. 2022, 10:855162. 10.3389\/fped.2022.855162","journal-title":"Front Pediatr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1055\/a-1703-0821","article-title":"Anticoagulation in pediatric patients","volume":"42","author":"Male C","year":"2022","unstructured":"Male C. Anticoagulation in pediatric patients. Hamostaseologie. 2022, 42:46-53. 10.1055\/a-1703-0821","journal-title":"Hamostaseologie"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-26150-w","article-title":"Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients-a prospective interventional study","volume":"12","author":"Takai S","year":"2022","unstructured":"Takai S, Nakanishi N, Yokota I, et al.. Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients-a prospective interventional study. Sci Rep. 2022, 12:21569. 10.1038\/s41598-022-26150-w","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/350127-rivaroxaban-treatment-in-pediatric-patients-with-hematologic-malignancies-and-venous-thromboembolism-a-report-of-four-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T07:38:00Z","timestamp":1746430680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/350127-rivaroxaban-treatment-in-pediatric-patients-with-hematologic-malignancies-and-venous-thromboembolism-a-report-of-four-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.83487","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}